Bellerophon Therapeutics, Inc. 4
4 · Bellerophon Therapeutics, Inc. · Filed Feb 23, 2015
Insider Transaction Report
Form 4
Luehring Jens
Director10% Owner
Transactions
- Purchase
Common Stock
2015-02-19$12.00/sh+358,916$4,306,992→ 1,629,804 total(indirect: See footnote)
Footnotes (1)
- [F1]These shares are owned directly by Linde North America, Inc. ("Linde"). Jens Luehring is a director and chief financial officer of Linde. Mr. Luehring disclaims beneficial ownership of all shares held by Linde, except to the extent of his pecuniary interest therein.